- Health Canada has granted NOC to Semaglutide Injection by Dr. Reddy’s Laboratories, making it the first company to secure approval for a generic version in Canada
- The once-weekly GLP-1 therapy is indicated for adults with type 2 diabetes to improve glycemic control, with approvals covering 2 mg and 4 mg pen presentations
- Backed by strong global clinical evidence, semaglutide improves HbA1c levels and is widely used as part of combination diabetes management strategies
- With ~3.9M Canadians living with diabetes, the approval strengthens access to more affordable GLP-1 options, supported by Dr. Reddy’s in-house API and manufacturing capabilities
Takeaways:
Dr. Reddy’s has become the first company to secure Health Canada approval for a generic semaglutide injection (Ozempic equivalent), with an NOC covering 2 mg and 4 mg once‑weekly pens for adults with type 2 diabetes.
Riding on a large global evidence base for HbA1c reduction and combination use in diabetes regimens, this launch will introduce a more affordable GLP‑1 option into what is already the world’s second‑largest semaglutide market, potentially easing access for some of the 3.9 million Canadians living with diabetes and leveraging Dr. Reddy’s in‑house API and manufacturing scale to compete on price and supply reliability.
Source: Businesswire
